The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence

Pfizer’s acquisition of King gave the company a chance to play in a new kind of market: abuse deterrent opioid pain relief formulations. Two years later, Pfizer is moving in the other direction, even as FDA’s actions validate the notion that there is an opportunity—and that the scale of Big Pharma can play a critical role.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet